1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Delayed Quote. Delayed Nasdaq Copenhagen - 05/20 10:59:42 am
761.3 DKK   +4.16%
05/20European ADRs Move Sharply Higher in Friday Trading
MT
05/20NOVO NORDISK : Berenberg remains Neutral
MD
05/16European ADRs Move Higher in Monday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

NOVO NORDISK : Receives a Sell rating from Jefferies

01/06/2022 | 02:55am EDT

Peter Welford from Jefferies retains his negative opinion on the stock with a Sell rating. The target price continues to be set at DKK 490.


© MarketScreener with dpa-AFX Analyser 2022
All news about NOVO NORDISK A/S
05/20European ADRs Move Sharply Higher in Friday Trading
MT
05/20NOVO NORDISK : Berenberg remains Neutral
MD
05/16European ADRs Move Higher in Monday Trading
MT
05/16NOVO NORDISK A/S : Share repurchase programme
GL
05/16NOVO NORDISK A/S : Share repurchase programme
GL
05/13U.S. FDA approves Eli Lilly's treatment for type 2 diabetes
RE
05/12NOVO NORDISK : Barclays gives a Buy rating
MD
05/11NOVO NORDISK A/S : Trading in Novo Nordisk shares by board members, executives and associa..
GL
05/11NOVO NORDISK : Deutsche Bank keeps its Buy rating
MD
05/10Novo Nordisk Starts Research Collaboration With Flagship Pioneering
MT
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Financials
Sales 2022 166 B 23 554 M 23 554 M
Net income 2022 52 875 M 7 494 M 7 494 M
Net cash 2022 4 087 M 579 M 579 M
P/E ratio 2022 32,4x
Yield 2022 1,51%
Capitalization 1 729 B 245 B 245 B
EV / Sales 2022 10,4x
EV / Sales 2023 9,16x
Nbr of Employees 49 295
Free-Float 69,6%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | MarketScreener
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 761,30 DKK
Average target price 791,88 DKK
Spread / Average Target 4,02%
EPS Revisions
Managers and Directors
Lars Fruergaard Jørgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Henrik Ehlers Wulff Senior Vice President-Diabetes API
Stephen Gough Global Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S3.58%245 099
JOHNSON & JOHNSON1.68%465 705
PFIZER, INC.-11.14%294 404
ELI LILLY AND COMPANY8.19%269 013
ABBVIE INC.11.53%266 851
ROCHE HOLDING AG-15.67%266 707